We offer turnkey kitchen solutions customized to meet the specific needs of restaurants, hotels, cafeterias, catering units, and more
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Easy measuring: At 300 mg/mL, 1 unit = 0.01 mL = 3 mg on a U-100 insulin syringe
Optimizing metformin therapy in practice: tolerability, efficacy and outcomes
Talk to our team or book a consultation, in person or by telehealth.